Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
about
Hypophysitis: Evaluation and Management.Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects.Restored vision in a young dog following corticosteroid treatment of presumptive hypophysitis.In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Ipilimumab in melanoma.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesCentral hypothyroidism - a neglected thyroid disorder.Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series.The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.Adverse Events in Cancer Immunotherapy.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery.Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies.Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings.Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.Immune-related endocrine disorders in novel Immune checkpoint inhibition therapy.Isolated Adrenocorticotropic Hormone Deficiency and Severe Hypercalcemia After Destructive Thyroiditis in a Patient on Nivolumab Therapy With a Malignant Melanoma.Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.Immune Checkpoints as Therapeutic Targets in Autoimmunity
P2860
Q33801229-92ACACE1-645A-4193-9DB9-FD5BA3D587A1Q36098253-3746F896-3558-404D-87F7-F0A858F2AA8BQ36292314-EE62381C-10C4-4CD5-9FDE-ED76299D5674Q37681734-CA70A000-DAA3-4358-8E5F-0435F7EA8E91Q38884560-7F24F7B4-2A3D-46B0-B82E-B7F656DD49E6Q38893697-0A4A4C9A-124B-4F4D-8129-8715066F97ECQ39010566-FE939E0C-5EAE-4C92-AFD2-AE0BC0F70E84Q39332895-A3BAB8BE-830B-43AC-9372-8807FD0DFEF0Q39369955-306C492D-9D9A-4B74-858D-BA975897FBF6Q39402079-04E52422-3A0C-42CC-818F-C9257191495EQ39441719-7C5ADB62-C588-412B-A44D-B72C6949C95FQ42149055-3E97C853-1F8D-450D-A022-DFD2190587D6Q42378748-C4B5DE39-5C91-4EE5-9B8A-6678FBE36E96Q45026631-6ACFA6A0-57A7-43AA-9232-142C69CB4055Q45839919-711686B4-E5A9-416F-A582-065C1BC71FD7Q46876969-8008B731-D49D-4227-88A1-936A764D5CF4Q46884498-B48145C4-3A95-4765-8DF3-66F3AF063BE0Q47102520-9EED2394-FE7F-4EBE-BF0B-FF00959ABCD4Q47106542-0490780A-025A-497B-B2CD-A966C2BE0D8FQ47707565-34071D2A-D40B-4337-B073-6C5791FF53B7Q48289680-E740805A-FA35-44C7-8BCC-80CF33E18BEFQ50002478-51E9BE7A-AD73-4EEC-8792-A5DF6A24E960Q50355383-47D55845-9130-4925-A7A7-8B06C0D146C8Q50420603-02E26415-FC01-42AA-9C9B-82388DD1FEBBQ52338753-9FB37024-DD0A-4634-B102-599D7034E2E3Q52777255-71B55A81-CFD1-499F-B2DC-1C7B31567830Q53656848-646438A2-DA3E-49E7-95E1-A122530FD2A9Q55401897-A1D64DC3-3DD1-4651-BD16-AED5CE969EF0Q55426703-A5088905-6BD1-4F3A-8FF7-72BE4E2B4E0FQ57817465-0BF9E23C-2745-43A1-9644-91CDE54CBF65
P2860
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
@en
type
label
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
@en
prefLabel
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
@en
P2860
P1433
P1476
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.
@en
P2093
Alexander Faje
P2860
P2888
P356
10.1007/S11102-015-0671-4
P577
2015-07-18T00:00:00Z